HYBRID EVENT: You can participate in person at Rome, Italy or Virtually from your home or work.

4th Edition of International Conference on Tissue Engineering and Regenerative Medicine

September 19-21 | Rome, Italy

September 19 -21, 2024 | Rome, Italy
TERMC 2024

A C Matin

A C Matin, Speaker at Regenerative Medicine Conferences
Stanford University School of Medicine, United States
Title : Side effect free cancer chemotherapy by directed gene delivery using nanomaterials


Side effect-free cancer chemotherapy is an urgent need, which can be met by prodrug therapies (GDEPTs). Prodrugs are harmless but bacterial/viral gene products can convert them into potent drugs that can be confined to tumors by ensuring delivery of the activating gene exclusively to cancer. GDEPTs lack of success so far is due to low gene delivery/expression; insufficient bystander effect; and use of viruses in delivering the gene. Also , direct injection into the cancer had been needed, which excluded treatment of unreachable cancers. We used 1. Our newly discovered prodrug, CNOB (C16H7CIN2O4); it generates the drug, MCHB (C16H9CIN2O2) which is fluorescent and can be quantitatively visualized in living mice, permitting facile elucidation of measures to ensure on-target activation. 2. Exosomes (EVs), for gene delivery; these are largely nonimmunogenic. 3. As CNOB is not yet clinically tried, we have now used the clinically tested prodrug CB1954 (tretazicar) at its safe human dose. And 4. mRNA instead of DNA as gene; the former is more efficient in gene expression. In-vitro transcribed (IVT) mRNA of our humanized and improved HChrR6 enzyme that activates tretazicar was loaded in HER2- targeting EVs. This (done for the first time) required several steps. Determining that the mRNA retained its functionality through this process was not feasible using tretazicar, but our discovery that HChrR6 enzyme can also activate CNOB enabled us to do this simply by ascertaining that the HChrR6 mRNA translated product generated fluorescence from CNOB. Systemic administration of the mRNA loaded and HER2-directed EVs (“EXODEPTs”) and tretazicar completely cured athymic mice with implanted orthotopic human HER2+ breast cancer xenografts without injuring other tissues/organs. HER2+ tumor ablation is immunogenic, so it is likely that recruiting immunity will enhance this GDEPT. Immune competent FVB/NJ mice that spontaneously develop HER2+ breast cancer provide a means for testing this to pave the way for the clinical transfer of this GDEPT. Any disease overexpressing a marker can be treated by this approach. EVs can cross the blood brain barrier, so brain metastasized cancers can possibly also be treated. Lipid nanoparticles too have unique advantages in targeted gene delivery


A C Matin is an Indian-American microbiologist, immunologist, academician and researcher. He is a professor of microbiology and immunology at Stanford University School of Medicine. Matin has published over 100 research papers plus several reviews and has many patents registered in his name. His research is focused on bio-molecular engineering, cellular resistance and virulence, drug discovery, biology of microgravity, bioremediation, stress promoters, stress sensing, and biotechnology. He has made pioneering research contributions in biology and physiology of mixotrophy, starvation responses at the cellular and genetic levels, bacterial multidrug and biofilm resistance, role of G proteins in starvation and motility, discovery of an imageable cancer prodrug, specific drug targeting and the development of heritable contrast agent for molecular resonance imaging. Matin's work on antibiotic resistance along with his work as a principal investigator on E. coli AntiMicrobial Satellite (EcAMSat) system resulted in NASA sending E. coli to space for astronaut health protection in 2017. He is the recipient of NASA honor award for the ECAMSAT Project. Matin was the editor-in-chief of Open Access Journal of Applied Sciences.